Severe hypersensitivity reaction: case report

A 39-year-old woman developed severe hypersensitivity reaction during treatment with ofatumumab for thrombotic thrombocytopenic purpura (TTP). She had a history of anaphylaxis due to rituximab, and she received a single dose of ofatumumab for TTP [dose not stated] in October 2017 (ADAMTS13 activity was less than 5%). Fifteen minutes after the initiation of ofatumumab infusion, she developed a generalised rash with hypotension. Her ofatumumab therapy was immediately stopped, and the hypotension was resolved with saline infusion treatment. Later, she was treated with ciclosporin and ADAMTS13 activity normalised within 4 weeks.

**Author comment:** "We observed a severe hypersensitivity reaction after the infusion of ofatumumab in a 39-year-old woman."

Aubart FC, et al. More on Ofatumumab for TTP. New England Journal of Medicine 378: 1364-1365, No. 14, 5 Apr 2018. Available from: URL: http://doi.org/10.1056/NEJMc1801263 - France